INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market saleVerified data

Bulis Veronica Sanchez sold LYEL

VP, Corporate Controller · Lyell Immunopharma, Inc. · Common Stock

Side
SELL
Value
$3,848
Shares
239
Price
$16.1
Executed
Nov 10, 2025
Disclosed
Nov 12, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 10 executedNov 12, 2025 disclosed

LYEL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
31/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+1 / 25

    $4K reported value · 2.5% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · LYEL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    21
    AM
    Aguirre Jarrad MattieuChief Medical Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$3,642
    422 sh
    		Oct 12, 2026Oct 13, 2026
    traded Oct 12, 2026
    		+1dSEC FORM 4

    Evidence

    17
    SD
    Shook DavidChief Medical Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$6,350
    500 sh
    		Sep 10, 2026Sep 10, 2026
    traded Sep 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    AM
    Aguirre Jarrad MattieuChief Medical Officer
    LYELLyell Immunopharma, Inc.
    Grant or award
    		A—
    47.5K sh
    		Sep 10, 2026Sep 10, 2026
    traded Sep 10, 2026
    		+0dSEC FORM 4

    Evidence

    31
    HJ
    Hill Stephen J.Chief Operating Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$15K
    989 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    31
    LK
    Lee Gary K.Chief Scientific Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$23K
    1,457 sh
    		Aug 21, 2026Aug 25, 2026
    traded Aug 21, 2026
    		+4dSEC FORM 4

    Evidence

    27
    LK
    Lee Gary K.Chief Scientific Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$1,879
    131 sh
    		Aug 10, 2026Aug 11, 2026
    traded Aug 10, 2026
    		+1dSEC FORM 4

    Evidence

    27
    BS
    Bulis Veronica SanchezVP, Corporate Controller
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$8,905
    621 sh
    		Aug 10, 2026Aug 11, 2026
    traded Aug 10, 2026
    		+1dSEC FORM 4

    Evidence

    27
    HJ
    Hill Stephen J.Chief Operating Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$1,276
    89 sh
    		Aug 10, 2026Aug 11, 2026
    traded Aug 10, 2026
    		+1dSEC FORM 4

    Evidence

    37
    LK
    Lee Gary K.Chief Scientific Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$2,460
    130 sh
    		May 11, 2026Jun 15, 2026
    traded May 11, 2026
    		+35dSEC FORM 4

    Evidence

    37
    HJ
    Hill Stephen J.Chief Operating Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$1,684
    89 sh
    		May 11, 2026Jun 15, 2026
    traded May 11, 2026
    		+35dSEC FORM 4

    Evidence

    37
    BS
    Bulis Veronica SanchezVP, Corporate Controller
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$4,103
    217 sh
    		May 11, 2026Jun 15, 2026
    traded May 11, 2026
    		+35dSEC FORM 4

    Evidence

    25
    SD
    Shook DavidChief Medical Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$25K
    1,977 sh
    		Jun 10, 2026Jun 11, 2026
    traded Jun 10, 2026
    		+1dSEC FORM 4

    Evidence

    31
    LK
    Lee Gary K.Chief Scientific Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$39K
    1,671 sh
    		Feb 11, 2026Feb 12, 2026
    traded Feb 11, 2026
    		+1dSEC FORM 4

    Evidence

    31
    HJ
    Hill Stephen J.Chief Operating Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$29K
    1,236 sh
    		Feb 11, 2026Feb 12, 2026
    traded Feb 11, 2026
    		+1dSEC FORM 4

    Evidence

    13
    HJ
    Hill Stephen J.Chief Operating Officer
    LYELLyell Immunopharma, Inc.
    Grant or award
    		A—
    4,000 sh
    		Feb 9, 2026Feb 11, 2026
    traded Feb 9, 2026
    		+2dSEC FORM 4

    Evidence

    27
    BS
    Bulis Veronica SanchezVP, Corporate Controller
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$5,872
    254 sh
    		Feb 10, 2026Feb 11, 2026
    traded Feb 10, 2026
    		+1dSEC FORM 4

    Evidence

    13
    LK
    Lee Gary K.Chief Scientific Officer
    LYELLyell Immunopharma, Inc.
    Grant or award
    		A—
    4,000 sh
    		Feb 9, 2026Feb 11, 2026
    traded Feb 9, 2026
    		+2dSEC FORM 4

    Evidence

    27
    HJ
    Hill Stephen J.Chief Operating Officer
    LYELLyell Immunopharma, Inc.
    Open-market sale
    		SELL$2,520
    109 sh
    		Feb 10, 2026Feb 11, 2026
    traded Feb 10, 2026
    		+1dSEC FORM 4

    Evidence

    17
    BS
    Bulis Veronica SanchezVP, Corporate Controller
    LYELLyell Immunopharma, Inc.
    Grant or award
    		A—
    8,750 sh
    		Feb 10, 2026Feb 11, 2026
    traded Feb 10, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SD
    Shook DavidChief Medical Officer
    LYELLyell Immunopharma, Inc.
    Grant or award
    		A—
    50.0K sh
    		Feb 10, 2026Feb 11, 2026
    traded Feb 10, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002095702-25-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 10, 2025
    Published
    Nov 12, 2025
    Ingested by INSIDER
    Nov 5, 04:33 UTC
    Last re-read
    Nov 5, 04:33 UTC

    Extracted facts

    Filer
    Bulis Veronica Sanchez
    Role
    VP, Corporate Controller
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Lyell Immunopharma, Inc.
    Ticker
    LYEL
    Shares
    239
    Price per share
    $16.1
    Value
    $3,848
    Execution date (reported)
    Nov 10, 2025
    Owned after transaction
    9,213 shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 239
    • Price: $16.1

    = $3,848

    What this establishes

    Bulis Veronica Sanchez filed this Form 4 reporting a open-market sale of LYEL on Nov 10, 2025. It became public on Nov 12, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    VP, Corporate Controller
    Bulis Veronica Sanchezcik:0002095702
    Issuer
    Lyell Immunopharma, Inc.cik:0001806952

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.